Logo

TCRT

Alaunos Therapeutics, Inc.

TCRT

Alaunos Therapeutics, Inc. • NASDAQ
$3.27 ▼ -2.68% (-0.09)
Market Cap $7.30 M
52w High $6.20
52w Low $1.31
Dividend Yield 0%
P/E -1.42
Volume 20.71K
Outstanding Shares 2.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.187M ▲ $-1.159M ▼ 0% $-0.55 ▲ $-1.159M ▼
Q2-2025 $0 ▼ $853.999K ▼ $-1.051M ▲ 0% ▲ $-0.63 ▲ $-1.038M ▲
Q1-2025 $2K ▼ $1.094M ▲ $-1.073M ▼ -53.65K% ▼ $-0.67 ▼ $-1.073M ▼
Q4-2024 $4K ▲ $759K ▼ $-742K ▲ -18.55K% ▼ $-0.46 ▲ $-742K ▲
Q3-2024 $0 $1.15M $-1.127M 0% $-0.7 $-1.127M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.938M ▼ $3.724M ▼ $921K ▼ $2.803M ▼
Q2-2025 $2.879M ▲ $4.735M ▲ $1.074M ▲ $3.661M ▲
Q1-2025 $319K ▼ $2.12M ▼ $1.062M ▲ $1.058M ▼
Q4-2024 $1.091M ▼ $2.755M ▼ $692K ▼ $2.063M ▼
Q3-2024 $1.683M $3.55M $826K $2.724M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.159M ▼ $-844K ▼ $-97K ▼ $0 ▼ $-941K ▼ $-941K ▼
Q2-2025 $-1.051M ▲ $-701K ▲ $0 $3.261M ▲ $2.56M ▲ $-701K ▲
Q1-2025 $-1.073M ▼ $-772K ▼ $0 $0 $-772K ▼ $-772K ▼
Q4-2024 $-742K ▲ $-592K ▲ $0 $0 $-592K ▲ $-592K ▲
Q3-2024 $-1.127M $-781K $0 $0 $-780K $-781K

Five-Year Company Overview

Income Statement

Income Statement Alaunos has effectively been a pre‑revenue company for years, with no meaningful sales and recurring losses tied to research and overhead. The business model so far has been to spend on development in hopes of future products, not to generate current income. While the loss level appears to have been trimmed somewhat over time, the company has not crossed any profitability milestones, and per‑share losses look especially large because of repeated reverse stock splits. Overall, the income statement reflects a company still in the “cash‑burning science project” phase rather than an operating business with commercial traction.

Balance Sheet

Balance Sheet The balance sheet has steadily shrunk, with cash and total assets declining over the last several years and shareholder equity eroding to a very thin layer. Debt has not been a major burden recently, but that is mostly because the overall balance sheet is small, not because the company is financially strong. This leaves Alaunos with limited reserves to absorb setbacks or fund new initiatives on its own. The company’s most important assets are its scientific platforms and intellectual property, which do not show up clearly in these figures, but from a pure financial strength perspective the balance sheet looks fragile.

Cash Flow

Cash Flow Cash flow trends underline the same story: Alaunos has consistently used cash in its operations and has not generated any meaningful internal cash to fund itself. Investment spending on equipment and facilities has been modest, which is typical for a lean biotech, but operating and free cash flows have remained negative year after year. This means the company has depended on outside capital and transactions to survive. With a shrinking cash base, the runway appears limited unless new funding, partnerships, or asset sales materialize.

Competitive Edge

Competitive Edge From a competitive standpoint, Alaunos sits in a difficult spot. It operates in an intensely competitive field—cell and gene therapies for cancer—where many better‑funded peers are advancing clinical programs. Alaunos once aimed to stand out with a faster, potentially cheaper manufacturing approach and a library of T‑cell receptors, but winding down its only clinical trial and cutting much of its workforce has weakened that position. With no active clinical pipeline and constrained finances, the company’s bargaining power versus potential partners is modest, and its ability to compete as a standalone player is highly uncertain.

Innovation and R&D

Innovation and R&D Scientifically, Alaunos still has interesting technology: a non‑viral gene transfer system and the hunTR platform for discovering T‑cell receptors aimed at cancer mutations. These platforms could, in theory, offer manufacturing advantages and a steady stream of new targets. However, the company has stepped back from running its own trials and is now more focused on extracting value from the platform—through partnerships, licensing, or other deals—rather than pushing products toward market itself. The big risk is that the science remains largely unproven in later‑stage clinical settings, so the gap between promising technology and commercially validated therapies is still wide.

Summary

Overall, Alaunos looks like a classic early‑stage biotech that has run into a financial wall before it could fully test or commercialize its ideas. The income statement shows no revenues and ongoing losses, the balance sheet is thin, and cash flows are negative, leaving little room for missteps. On the positive side, the company does possess distinctive technology and a discovery platform that might appeal to partners, especially in the T‑cell therapy space. But the decision to halt its main trial and cut staff signals that the story has shifted from building a pipeline to trying to monetize remaining assets. The future now hinges less on operating performance and more on whether strategic deals can be struck in time, making the situation highly uncertain and very dependent on external counterparties and capital markets conditions.